LWLiyang Wang

Liyang Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Liyang Wang has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • Chao Li

    Department of Head and Neck Surgery, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China

    1 shared publication
  • Cuirong Gu

    Department of Biochemistry & Molecular Biology, Sichuan Cancer Insititute, No.55, Section 4, South Renmin Road, Chengdu, 610041, People's Republic of China

    1 shared publication
  • Dongmei Hu

    Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China

    1 shared publication
  • Hang Zhou

    From the Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China

    1 shared publication
  • Hua Xie

    From the Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China

    1 shared publication
  • Huan Huang

    Department of Medical oncology, Wuming Hospital Affiliated to Guangxi Medical University, Nanning, 530000, China

    1 shared publication

Latest Publications

  • Open Access

    Epstein-Barr virus-associated tumors: commonalities in pathogenesis and the tumor immune microenvironment

    by Xiyi Wang, Dongmei Hu, Renqin Li, Wenjun Liao, Chao Li, Qiuhan Liu, Jiayao Li, Qiaohua Li, Wenpei Guo, Liyang Wang, et al.

    Epstein-Barr virus (EBV) is associated with a wide spectrum of lymphoid and epithelial malignancies. This review provides a comprehensive pan-tumor perspective on the convergent oncogenic mechanisms, immune microenvironment characteristics, and shared therapeutic vulnerabilities across EBV-related cancers. We systematically summarize EBV infection and latency patterns, highlighting key shared signaling networks (e.g., NF-κB, PI3K/AKT) alongside nuanced immune evasion strategies, such as HLA modulation and steric immune blockade. By bridging these molecular insights with clinical translation, we evaluate emerging therapeutic paradigms, including immune checkpoint inhibitors, EBV-specific T-cell therapies, neutralizing antibodies, and mRNA vaccines. Ultimately, this synthesis underscores the potential of exploiting shared viral vulnerabilities to develop pan-tumor targeted therapies, offering a strategic roadmap for future clinical development.


  • Open Access

    All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells

    by Wenxiu Yao, Liyang Wang, Huan Huang, Xin Li, Pinjia Wang, Kun Mi, Jia Cheng, Huifen Liu, Cuirong Gu, Lingxiao Huang, et al.

    Background: The enrichment of cancer stem cell-like cells (CSCs) has been considered to be responsible for tumor progression after an initial response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small cell lung adenocarcinoma (NSCLC/ADC). CSCs with ALDH1A1bright/CD44highexpression contribute to the TKIs resistance in NSCLC/ADC cells. All-trans retinoic acid (ATRA) has been shown to be a potential targeted therapy against CSCs due to its ability to inhibit ALDH1A1 activity. We therefore investigated whether ATRA could circumvent the resistance to improve the response to gefitinib in NSCLC/ADC cells.Methods: Treatment of NSCLC/ADC A549 and H1650 cells with gefitinib enriched the gefitinib surviving cells (GSCs). The expression of ALDH1A1 and CD44 and the IC50 values for gefitinib were determined by flow cytometry (FCM) and crystal violet assay in GSCs and ATRA-treated GSCs, respectively. Using DEAB as the positive control, direct inhibitory effect of ATRA on ALDH1A1 activity was determined by ALDEFLUOR assay,Results: GSCs showed higher expression of ALDH1A1 and CD44 and IC50 values for gefitinib than their respective parental cells, suggesting that gefitinib can lead to propagation of CSC-enriched gefitinib-resistant cells. Treatment with ATRA was found to significantly reduce the increased expression of ALDH1A1 and CD44 and the IC50 values for gefitinib in A549GSC and H1650GSC cells, and ATRA could directly inhibit active ALDH1A1 as compared to DEAB.Conclusion: Our findings suggest that combination treatment with ATRA prevents gefitinib-induced enrichment of ALDH1A1bright/CD44highCSCs and enhances gefitinib-induced growth inhibition of NSCLC/ADC cells.


  • Open Access

    Efficacy of carboplatin-based preoperative chemotherapy for triple-negative breast cancer

    by Li-Yang Wang, Hua Xie, Hang Zhou, Wen-Xiu Yao, Xin Zhao, Yi Wang

    Efficacy of carboplatin-based preoperative chemotherapy for triple-negative breast cancer. A meta-analysis of randomized controlled trials